1. previous chemotherapy, radiation therapy, immunotherapy, or other anticancer therapy within 14 days

2. Clinically significant gastrointestinal disorder or malabsorption syndrome

3. Acute digestive disorder

4. major organ failure

5. Significant cardiac disorders

6. major operation of a main organ in 4 weeks

7. Untreated symptomatic brain metastasis

8. pregnant or nursing

9. previously diagnosed Interstitial lung disease(ILD)

10. previously treated with irreversible pan-HER inhibitor including Afatinib or Ruxolitinib

11. previously experienced hypersensitivity to an ingredient of the study drug

12. must receive CYP3A4 inducer or inhibitor persistently during the study period.

13. HIV positive or active hepatitis

14. threatening patient's safety is predicted

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)